1 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow EMD 525797 250 mg: new trials by email Literature Review of EMD 525797 250 mg trials Research Report on EMD 525797 250 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer EMD 525797 250 mg, EMD 525797 500 mg, EMD 525797 750 mg - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Merck KGaA, Darmstadt, Germany | 232 | 2009-10-01 | 2016-03-30 |
Merck KGaA, Darmstadt, Germany (1)
Belgium (1) · Bulgaria (1) · Cyprus (1) · Czechia (1) · Germany (1) · Greece (1) · Hungary (1) · Israel (1) · Poland (1) · Russia (1) · Spain (1) · United Kingdom (1)